Clinical Trial Update: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of Apitegromab in patients with later-onset spinal muscular atrophy who are treated with nusinersen or r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Apitegromab (SRK-015)
• EVRYSDI (risdiplam)
• Spinraza (nusinersen)

Snippet

Sponsor: Scholar Rock, Inc. | Conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 3 | Status: COMPLETED